BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Tolerx, Inc. 

300 Technology Square
3rd Floor
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-354-8100 Fax: 617-354-8300


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Tolerx, Inc. is a biopharmaceutical company engaged in discovering and developing new therapies designed to treat patients with immune related diseases - such as type 1 diabetes, psoriasis, and others - by reprogramming the immune system following a short course of therapy. Tolerx is developing its CD3 monoclonal antibody, otelixizumab, in collaboration with GlaxoSmithKline and the Juvenile Diabetes Research Foundation. Tolerx is developing with Genentech, a CD4 monoclonal antibody, MTRX1011. Tolerx is also engaged in the preclinical development of other antibodies that may shift or modulate the immune system.

For more information about Tolerx, please visit the company’s website at www.tolerx.com.


 Key Statistics


Email: info@tolerx.com
Ownership: Private

Web Site: Tolerx, Inc.
Employees:
Symbol: 
 









 Company News
Tolerx, Inc. Cuts Staff, Auctioning Assets After Phase 3 Failure 10/7/2011 9:31:26 AM    More...
Tolerx, Inc. Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses 4/5/2011 7:18:12 AM    More...
Tolerx, Inc. and GlaxoSmithKline (GSK) Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 3/11/2011 7:13:01 AM    More...
Tolerx, Inc. Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody 2/9/2011 7:55:27 AM    More...
Tolerx, Inc. Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 12/14/2010 7:21:11 AM    More...
Tolerx, Inc. and the Cancer Research Institute Enter Collaboration to Accelerate Development of TRX518, a First-in-Class Anti-GITR Antibody for Cancer Treatment 12/1/2010 7:29:16 AM    More...
Tolerx, Inc. Forms Scientific Advisory Board to Advance Research in Type 1 Diabetes 11/2/2010 11:24:02 AM    More...
Tolerx, Inc. Presents Research at European Diabetes Meeting and Enrolls First Patient in Europe in the DEFEND-2 Phase 3 Clinical Study in Type 1 Diabetes 9/23/2010 8:33:27 AM    More...
Tolerx, Inc. Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 8/4/2010 9:16:59 AM    More...
Tolerx, Inc. Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes 6/28/2010 9:12:55 AM    More...
1234